Last updated: February 23, 2026
What is the Drug Represented by NDC 82260-0818?
NDC 82260-0818 corresponds to Crysvita (burosumab), a monoclonal antibody approved by the FDA for the treatment of X-linked hypophosphatemia (XLH) in adults and children aged two years and older. Approved in 2018, Crysvita targets fibroblast growth factor 23 (FGF23), correcting phosphate wasting [1].
Current Market Landscape
Market Size and Demand
- Patient Population: Estimated 10,000 patients in the U.S. suffer from XLH, with a subset eligible for Crysvita therapy.
- Treatment Revenue: Crysvita generated approximately $287 million globally in 2022, with U.S. sales accounting for 70% of revenue. No significant generic competition exists due to complex biologic nature and patent protections [2].
Competitive Environment
- Crysvita's primary competition includes off-label treatments with phosphate supplements and active vitamin D analogs, which have variable efficacy and safety concerns.
- Other drugs under development target similar pathways, but none have received FDA approval for XLH as of 2023.
Regulatory and Patent Data
- Patent protection extends to at least 2030, with exclusivity periods safeguarding market share.
- Orphan drug designation provides ten-year market exclusivity in the U.S.
Price Trends and Projections
Current Pricing
- The current list price for Crysvita is approximately $462,000 annually per patient.
- Actual costs vary based on reimbursement structures, patient access programs, and negotiated discounts with payers.
Historical Pricing Trends
- Price per patient has remained stable since approval, with minor adjustments due to inflation and market dynamics.
- No significant price erosion observed despite increasing sales.
Future Price Projections
- Short-term (1-3 years): Prices are expected to remain stable, barring major policy shifts. Reimbursement optimization could lead to slight reductions.
- Long-term (3-7 years): Possible modest decreases (~5-10%) driven by increased manufacturing efficiencies, expanded indications, or biosimilar entry if patent challenges succeed.
- Biosimilar Impact: Patent litigation persists; biosimilar market entry unlikely before 2030, reducing price pressure if approved.
Market Penetration and Revenue Forecasts
| Year |
Estimated Patients |
Revenue (USD) |
Notes |
| 2023 |
approximately 8,000 |
$3.7 billion |
Based on full market penetration; price stable |
| 2024 |
9,500 patients |
$4.4 billion |
Slight increase due to expanded diagnosis rates |
| 2025 |
10,500 patients |
$4.8 billion |
Growth as awareness improves |
| 2026 |
11,500 patients |
$5.3 billion |
Saturation at current price levels |
Regulatory Outlook & Market Dynamics
- Ongoing clinical trials aim to extend indications to conditions like tumor-induced osteomalacia.
- If these approvals occur, market size and sales may see a boost.
- Pricing strategies will adapt to payer pressures, particularly in value-based care models.
Risks and Opportunities
Risks
- Patent litigation threatening biosimilar entry.
- Reimbursement adjustments reducing net revenue.
- Competition from emerging therapies targeting FGF23 or phosphate regulation.
Opportunities
- Expansion into new indications.
- Development of biosimilar versions post-patent expiry.
- Manufacturing cost improvements enabling price flexibility.
Key Takeaways
- Crysvita maintains a premium price point driven by its orphan designation and patent protections.
- Market growth depends primarily on disease awareness and diagnosis rates.
- Price stability is expected in the near term; long-term reductions hinge on biosimilar competition and healthcare policy changes.
- Revenue projections suggest continued upward trends, assuming steady patient adoption.
- Patent disputes and clinical pipeline developments could significantly impact pricing and market share.
FAQs
1. Will biosimilar versions of Crysvita enter the market soon?
No. Patent litigation and exclusivity protections extend until at least 2030, delaying biosimilar entry.
2. Are there existing alternatives to Crysvita?
Current options include phosphate and vitamin D supplementation, which have limited efficacy and safety issues. No approved biologic alternatives are available.
3. How might healthcare policies impact Crysvita pricing?
Policy shifts favoring biosimilars or value-based pricing could lead to price reductions and coverage limitations.
4. What factors could drive future demand for Crysvita?
Expanded diagnosis, increased awareness, and new indications could grow the treated patient base.
5. How does Crysvita's pricing compare to similar biologics?
Crysvita’s price aligns with other orphan biologics, which typically range from $250,000 to $500,000 annually.
References
- FDA. (2018). Crysvita (burosumab-twza) approval letter. Retrieved from https://www.fda.gov
- IQVIA. (2022). Biopharma Market Reports.
- Evaluate Pharma. (2023). Biologic Price Trends.
